Myriad Genetics

Shobita Parthasarathy has called for serious patent system reforms in a July 31 article she authored in The Conversation. Such reforms, she said, could "include increasing opportunities for the public to participate in patent decision-making,...

The American Civil Liberties Union (ACLU) recently filed a petition asking the U.S. Supreme Court to review a decision upholding patents on human genes BRCA1 and BRCA2. The Court will soon decide the case involving Myriad Genetics, Inc., which owns...

In the article, "Ownership of Genes Stops Research," at the New York Times, Shobita Parthasarathy, associate professor of public policy, responds to the question of whether companies should be allowed to patent genes. Parthasarathy reasons that, as...

In honor of National Cancer Survivors Day Shobita Parthasarathy was interviewed by the MIT Press about cancer research and health care advances. In the Q&A format blog post, Parthasarathy spoke about gene patenting—specifically BRCA 1 and BRCA 2,...

Even before we had mapped the human genome, American entrepreneurs had begun to stake claims to it. Over the last two decades, the U.S. Patent Office has issued more than 5,000 patents on parts of the human genome, leaving an alarming 20 percent of...

Shobita Parthasarathy was interviewed by German Public Radio about recent debates on the legality of patenting human genes. Since a narrowly decided Supreme Court ruling in the 1980s, the U.S. Patent Office has allowed patents for a variety of life...